SELLAS Life Sciences Group, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
SELLAS Life Sciences Group, Inc. (SLS) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $0 for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-05.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2015-12-04
- SELLAS Life Sciences Group, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2014-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2014-06-30 was $0.00.
- SELLAS Life Sciences Group, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2013-09-30 was -$2.11M.
- SELLAS Life Sciences Group, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2013-06-30 was -$3.13M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 126 month |
|---|---|---|---|---|---|
| 2014-09-30 | $0.00 10-Q · filed 2014-11-05 | $0.00 derived: sum of 2 quarters · filed 2014-11-05 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | ||||
| 2013-09-30 | -$2.11M 10-Q · filed 2014-11-05 | -$5.24M derived: sum of 2 quarters · filed 2014-11-05 | $1.79M 10-Q · filed 2014-11-05 | ||
| 2013-06-30 | -$3.13M 10-Q · filed 2014-08-11 | $3.90M 10-Q · filed 2014-08-11 | $6.58M 10-Q · filed 2013-08-09 | ||
| 2013-03-31 | $7.03M 10-Q · filed 2014-05-06 | ||||
| 2012-12-31 | $2.68M 8-K · filed 2015-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |